Related Experiment Video
Updated: Aug 6, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
New drugs for hepatitis C virus (HCV)
1Virology Research Unit, GlaxoWellcome Medicine Research Centre, Stevenage, Hertfordshire, UK.
Summary
Hepatitis C virus (HCV) therapies like interferon-alpha (IFN-alpha) show limited efficacy and side effects. New treatments are needed for better antiviral activity and fewer adverse events.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Interferon-alpha (IFN-alpha) is a standard therapy for non-A non-B hepatitis (NANBH) caused by hepatitis C virus (HCV).
- Limited efficacy and significant side effects of IFN-alpha necessitate the search for improved therapeutic options.
- Combination therapy with ribavirin has shown synergistic effects but often fails to provide lasting benefit.
Purpose of the Study:
- To review the progress in developing alternative therapies for HCV.
- To discuss the prospects for new, more effective treatments with reduced side effects.
Main Methods:
- Review of existing literature on IFN-alpha therapy for HCV.
- Analysis of combination therapies involving IFN-alpha and other agents.
- Evaluation of strategies to improve IFN-alpha potency and tolerability.
Main Results:
- Adjusting dosing, delivery methods, and treatment duration for IFN-alpha has been explored.
- Synergistic effects observed with IFN-alpha and ribavirin combination therapy.
- Majority of patients do not achieve sustained therapeutic benefit from current combination therapies.
Conclusions:
- Current therapies for HCV, including IFN-alpha and ribavirin combinations, remain insufficient for many patients.
- Ongoing research is crucial for identifying novel therapeutic candidates with enhanced antiviral activity and improved safety profiles.
- Future prospects lie in developing new agents to overcome limitations of existing HCV treatments.
More Related Videos
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...